DFN-11 Injection in Episodic Migraine With or Without Aura

Completed · Phase 3 · Has a placebo group

Conditions studied: Episodic Migraine

In brief

Safety and Efficacy of DFN-11 in patients with episodic migraines with or without aura.

Key facts

Study ID: NCT02569853
Run by: Dr. Reddy's Laboratories Limited
People needed: 268
Starts: 2015-09-21
Expected to finish: 2018-02-26
Last updated by the study team: 2018-07-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

If female, a subject must have a negative serum pregnancy test at screening, does not plan to become pregnant during the study, and is not lactating
If female, a subject also must have a negative urine pregnancy test at all subsequent study visits after the Screening Visit, and agree to practice a reliable form of contraception or abstinence during the study. Acceptable forms of contraception include implants, injectables, combined oral contraceptives, an intrauterine device, a vasectomized partner, an exclusively female partner, and double-barrier methods.
If male (with female partner), a subject must agree to practice a reliable form of contraception or abstinence during the study.
A history of episodic migraine who experience 2 to 6 migraine attacks a month for at least the past 12 months with no more than 14 migraine headache days per month, and with 48 hours of headache free time between migraine headaches
Have migraine with or without aura; if with aura, the aura cannot last longer than 60 minutes

You may not qualify if…

Minors, even if they are in specified study age range
Medication overuse headache as defined by ICHD II:
Opioids ≥ 10 days a month during the 90 days prior to screening
Combination medications (e.g., Fiorinal®) ≥ 10 days a month during the 90 days prior to screening
Nonsteroidal anti-inflammatory drugs (NSAIDs) or other simple medications > 14 days a month during the 90 days prior to screening
Triptans or ergots ≥ 10 days a month during the 90 days prior to screening
Subjects treated with onabotulinumtoxin A (Botox®) or other botulinum toxin treatment; or history of receiving such treatment during the 180 days prior to screening
On unstable dosages of migraine prophylactic medications during the 30 days prior to and through screening
Taking mini-prophylaxis for menstrual migraine
Subjects with hemiplegic or basilar migraine or other forms of neurologically complicated migraine
Subjects who have prolonged aura (i.e., more than 1 hour)
Cerebrovascular disease including but not limited to a history of stroke or transient ischemic attack (TIA)
A history of migralepsy (seizure following a migraine) or a concurrent diagnosis of seizure disorder
Subjects who cannot differentiate between a migraine headache and tension-type or cluster headache or other types of headache
Subjects with a history of more than occasional (based on Investigator's judgment) tension-type headache (distinct from migraine headache days count).
Subjects with a history of cluster headaches
Subjects with the diagnosis of "probable migraine" (ICHD II)
Ischemic coronary artery disease (CAD): including but not limited to angina pectoris, history of myocardial infarction or documented silent ischemia or coronary artery vasospasm, including Prinzmetal's angina
Subjects with Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders
Subjects with a history of congenital heart disease
A history of uncontrolled hypertension or screening systolic/diastolic > 140/90 mmHg
Have peripheral vascular disease including but not limited to ischemic bowel disease (IBD) and Raynaud's disease.
Any abnormal physiology and/or pathology which, in the opinion of the Investigator or Sponsor, which would be contraindicated for study participation and would not allow the objectives of the study to be met
Subjects who show any clinical laboratory or electrocardiogram (ECG) abnormality that in the opinion of the Investigator would endanger the subject or interfere with the study conduct. If the results of the clinical laboratory or ECG are outside of normal reference range the subject may still be enrolled but only if these findings are determined to be not clinically significant by the Investigator. This determination must be recorded in the subject's source document prior to enrolment.
Fridericia's corrected QT (QTcF) interval greater than 450 msec

Where it is running

Dr. Reddy's Investigational Site #18 — Santa Monica, California, United States
Dr. Reddy's Investigational Site #24 — Jacksonville, Florida, United States
Dr. Reddy's Investigational Site #23 — Maitland, Florida, United States
Dr. Reddy's Investigational Site #27 — Boise, Idaho, United States
Dr. Reddy's Investigational Site #20 — Watertown, Massachusetts, United States
Dr. Reddy's Investigational Site #19 — Ann Arbor, Michigan, United States
Dr. Reddy's Investigational Site #13 — Springfield, Missouri, United States
Dr. Reddy's Investigational Site #12 — Albuquerque, New Mexico, United States
Dr. Reddy's Investigational Site #10 — Williamsville, New York, United States
Dr. Reddy's Investigational Site #26 — Greensboro, North Carolina, United States
Dr. Reddy's Investigational Site #15 — Cleveland, Ohio, United States
Dr. Reddy's Investigational Site #21 — Mt. Pleasant, South Carolina, United States
Dr. Reddy's Investigational Site #25 — Memphis, Tennessee, United States
Dr. Reddy's Investigational Site #14 — Dallas, Texas, United States
Dr. Reddy's Investigational Site #16 — Hurst, Texas, United States
Dr. Reddy's Investigational Site #17 — West Jordan, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.